>
Australian Pharmaceutical Industries logo

API - Australian Pharmaceutical Industries Share Price

A$1.13 -0.0  -3.8%

Last Trade - 7:10am

Sector
Consumer Defensives
Size
Small Cap
Market Cap £321.2m
Enterprise Value £493.4m
Revenue £2.20bn
Position in Universe 392nd / 1907
Bullish
Bearish
Unlock API Revenue
Momentum
Relative Strength (%)
1m -13.5%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -14.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Aug 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
3,462 3,845 4,067 4,035 4,016 4,025 4,036 4,136 +3.1%
+17.0 +6.7 -1.9 +4.1 -56.1 +70.7 +15.7
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 28 February 2021,Australian Pharmaceutical Industries Ltd revenues decreased3% to A$1.98B. Net income decreased 27% to A$15.9M.Revenues reflect a decrease in demand for the Company'sproducts and services due to unfavorable market conditions.Net income also reflects FV Adjustments of FinancialInvestments decrease from A$6.9M (income) to A$0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

API Revenue Unlock API Revenue

Net Income

API Net Income Unlock API Revenue

Normalised EPS

API Normalised EPS Unlock API Revenue

PE Ratio Range

API PE Ratio Range Unlock API Revenue

Dividend Yield Range

API Dividend Yield Range Unlock API Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
API EPS Forecasts Unlock API Revenue
Profile Summary

Australian Pharmaceutical Industries Limited is a pharmaceutical distributor, and health and beauty retailer. The Company operates through two segments: Australia, which is engaged in the distribution of pharmaceutical, medical, health, beauty and lifestyle products to pharmacies, the purchase and sale of various health, beauty and lifestyle products within the retail industry, and the provision of retail services to pharmacies, and New Zealand, which manufactures and owns rights of pharmaceutical medicines and consumer toiletries. Its services include wholesale product delivery, retail services, marketing programs and business advisory services. Its brands include Priceline & Priceline Pharmacy, which is a health, beauty and wellbeing retailer; Soul Pattinson Chemist, which is a pharmacy brand; Pharmacist Advice, which offers professional service and advice; Club Premium, which is a club for independent pharmacies, and Pharmacy Best Buys, which offers a catalog program.

Directors
Last Annual August 31st, 2020
Last Interim February 28th, 2021
Incorporated April 19, 1910
Public Since June 16, 1997
No. of Shareholders: 13,670
No. of Employees: 5,105
Sector Consumer Defensives
Industry Food & Drug Retailing
Index S&P/ASX All Ordinaries , S&P/ASX 300 , ASX Small Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 492,656,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
API Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for API
Upcoming Events for API
Thursday 6th May, 2021
Dividend For API.AX - 0.0150 AUD
Friday 22nd October, 2021 Estimate
Full Year 2021 Australian Pharmaceutical Industries Ltd Earnings Release
Frequently Asked Questions for Australian Pharmaceutical Industries
What is the Australian Pharmaceutical Industries share price?

As of 7:10am, shares in Australian Pharmaceutical Industries are trading at A$1.13, giving the company a market capitalisation of £321.2m. This share price information is delayed by 15 minutes.

How has the Australian Pharmaceutical Industries share price performed this year?

Shares in Australian Pharmaceutical Industries are currently trading at A$1.13 and the price has moved by 4.91% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Australian Pharmaceutical Industries price has moved by -21.75% over the past year.

What are the analyst and broker recommendations for Australian Pharmaceutical Industries?

Of the analysts with advisory recommendations for Australian Pharmaceutical Industries, there are there are currently 1 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Australian Pharmaceutical Industries is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Australian Pharmaceutical Industries next release its financial results?

Australian Pharmaceutical Industries is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-02-28
What is the Australian Pharmaceutical Industries dividend yield?

The Australian Pharmaceutical Industries dividend yield is 1.7% based on the trailing twelve month period.

Does Australian Pharmaceutical Industries pay a dividend?

Last year, Australian Pharmaceutical Industries paid a total dividend of 0.02, and it currently has a trailing dividend yield of 1.7%. Looking ahead, shares in Australian Pharmaceutical Industries are due to go ex-dividend on 2021-05-06 and the next dividend pay date is 2021-06-04.

When does Australian Pharmaceutical Industries next pay dividends?

Australian Pharmaceutical Industries are due to go ex-dividend on 2021-05-06 and the next dividend pay date is 2021-06-04. The historic dividend yield on Australian Pharmaceutical Industries shares is currently 1.7%.

How do I buy Australian Pharmaceutical Industries shares?

To buy shares in Australian Pharmaceutical Industries you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Australian Pharmaceutical Industries?

Shares in Australian Pharmaceutical Industries are currently trading at A$1.13, giving the company a market capitalisation of £321.2m.

Where are Australian Pharmaceutical Industries shares listed? Where are Australian Pharmaceutical Industries shares listed?

Here are the trading details for Australian Pharmaceutical Industries:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: API
What kind of share is Australian Pharmaceutical Industries?

Based on an overall assessment of its quality, value and momentum, Australian Pharmaceutical Industries is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Australian Pharmaceutical Industries share price forecast 2021?

Shares in Australian Pharmaceutical Industries are currently priced at A$1.13. At that level they are trading at 17.79% discount to the analyst consensus target price of 0.00.

Analysts covering Australian Pharmaceutical Industries currently have a consensus Earnings Per Share (EPS) forecast of 0.083 for the next financial year.

How can I tell whether the Australian Pharmaceutical Industries share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Australian Pharmaceutical Industries. Over the past six months, the relative strength of its shares against the market has been -8.24%. At the current price of A$1.13, shares in Australian Pharmaceutical Industries are trading at 0.7% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Australian Pharmaceutical Industries PE Ratio?

The Australian Pharmaceutical Industries PE ratio based on its reported earnings over the past 12 months is 36.18. The shares are currently trading at A$1.13.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Australian Pharmaceutical Industries?

Australian Pharmaceutical Industries's management team is headed by:

Richard Vincent - CEO
Lee Ausburn - NID
Kenneth Gunderson Briggs - NEC
Peter Mendo - CFO
Jennifer Macdonald - NID
Anne Mustow - SEC
Janine Allis - NID
Clive Stiff - NID
Who are the major shareholders of Australian Pharmaceutical Industries?

Here are the top five shareholders of Australian Pharmaceutical Industries based on the size of their shareholding:

Washington H Soul Pattinson and Company Ltd Investment Advisor
Percentage owned: 19.3% (95.1m shares)
First Sentier Investors Investment Advisor
Percentage owned: 4.13% (20.3m shares)
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund
Percentage owned: 3.45% (17.0m shares)
DFA International Small Cap Value Portfolio Mutual Fund
Percentage owned: 2.05% (10.1m shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 2% (9.85m shares)
Similar to API
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.